HM15211 vs Pemvidutide

Head-to-head comparison of HM15211 (HM15211, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist) and Pemvidutide (Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyHM15211Pemvidutide
CategoryWeight ManagementWeight Management
Full NameHM15211, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonistPemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist
Molecular WeightN/AN/A
Half-LifeApproximately 1 weekApproximately 1 week
Amino AcidsN/AN/A
Typical DoseInvestigational; no established human doseTrial-dependent; once-weekly SC titration
RouteSubcutaneousSubcutaneous
Purity≥98%≥98%
Studies Count1218
Research StatusClinicalClinical

HM15211 Benefits

  • appetite suppression
  • greater fat oxidation
  • weight loss
  • improved metabolic markers

Pemvidutide Benefits

  • appetite suppression
  • body-weight reduction
  • improved liver-fat markers
  • better glycemic control

HM15211 Dosing

once-weekly subcutaneous injection|titration to effect|maintenance at tolerated dose

Pemvidutide Dosing

once-weekly subcutaneous injection|gradual dose escalation|maintenance at tolerated trial dose

HM15211 Side Effects

  • nausea
  • vomiting
  • reduced appetite

Pemvidutide Side Effects

  • nausea
  • vomiting
  • diarrhea

Research Overview

HM15211

Research has shown potent weight-reducing and metabolic effects in preclinical and translational studies. The compound is being developed as a next-generation incretin-based therapy.

Pemvidutide

Clinical studies have reported dose-dependent weight loss and favorable effects on liver fat and transaminases. It remains investigational and is not approved for obesity treatment.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

HM15211 stacks with:

metformintopiramate

Pemvidutide stacks with:

metformintopiramate
glp1gipglucagontriagonistobesitydual-agonistmash